
                                SEQUENCE LISTING

<110> Ernest S. Smith,
      Terrence Lee Fisher Jr.
      Maurice Zauderer
      

<120> HUMAN ANTI-CD100 ANTIBODIES
  

<130> 050827/340176

<150> 60/901530           
<151> 2007-02-14  

<160> 65

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 1
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 2
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 2
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 3
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 3
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Lys Gln Ser His Gly Glu Ser Phe Glu Trp Ile
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Asn Ser Leu Thr Tyr Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
        115                 120         


<210> 4
<211> 113
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 4
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Pro Gly
 1               5                  10                  15      
Glu Pro Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser
            20                  25                  30          
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln
        35                  40                  45              
Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
    50                  55                  60                  
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65                  70                  75                  80  
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
                85                  90                  95      
Asp His Thr Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
            100                 105                 110         
Lys
    


<210> 5
<211> 113
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 5
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly
 1               5                  10                  15      
Glu Lys Val Thr Met Asp Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser
            20                  25                  30          
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr His Gln Lys Pro Gly Gln
        35                  40                  45              
Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
    50                  55                  60                  
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65                  70                  75                  80  
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
                85                  90                  95      
Asp His Thr Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
            100                 105                 110         
Lys
    


<210> 6
<211> 118
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 6
Glu Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1               5                  10                  15      
Ser Leu Asn Leu Ser Cys Thr Ala Ser Gly Phe Asp Phe Ser Arg Tyr
            20                  25                  30          
Trp Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Gln Glu Trp Ile
        35                  40                  45              
Gly Glu Ile Asn Pro Gly Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu
    50                  55                  60                  
Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65                  70                  75                  80  
Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gln Gly Thr Tyr Tyr Thr Met Asp Tyr Trp Gly Gln Gly Thr
            100                 105                 110         
Thr Val Thr Val Ser Ser
        115             


<210> 7
<211> 106
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 7
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15      
Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Tyr
            20                  25                  30          
Ile Ser Trp Tyr Gln Asp Lys Pro Gly Lys Gly Pro Gly Leu Leu Ile
        35                  40                  45              
His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly
    50                  55                  60                  
Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro
65                  70                  75                  80  
Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Tyr Thr
                85                  90                  95      
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105     


<210> 8
<211> 25
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 8
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser
            20                  25  


<210> 9
<211> 10
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 9
Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Asp
 1               5                  10  


<210> 10
<211> 16
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 10
Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      


<210> 11
<211> 13
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 11
Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr
 1               5                  10              


<210> 12
<211> 25
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 12
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser
            20                  25  


<210> 13
<211> 25
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 13
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser
            20                  25  


<210> 14
<211> 10
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 14
Gly Tyr Thr Phe Thr Lys Tyr Tyr Met Asp
 1               5                  10  


<210> 15
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 15
Arg Val Asn Pro Tyr His Gly Phe Ala Thr Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 16
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 16
Arg Val Asn Pro Tyr His Gly Trp Ala Thr Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 17
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 17
Arg Val Asn Pro Tyr His Gly Tyr Ala Thr Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 18
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 18
Arg Val Asn Pro Tyr His Gly Gly Gly Thr Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 19
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 19
Arg Val Asn Pro Tyr His Gly Gly Ala Phe Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 20
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 20
Arg Val Asn Pro Tyr His Gly Gly Ala Val Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 21
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 21
Arg Val Asn Pro Tyr His Gly Gly Ala Trp Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 22
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 22
Arg Val Asn Pro Tyr His Gly Gly Ala Thr Phe Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 23
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 23
Arg Val Asn Pro Tyr His Gly Gly Ala Thr Pro Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 24
<211> 17
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 24
Arg Val Asn Pro Tyr His Gly Gly Ala Thr Val Asn Gln Lys Phe Lys
 1               5                  10                  15      
Gly
    


<210> 25
<211> 13
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 25
Glu Asp Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr
 1               5                  10              


<210> 26
<211> 13
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 26
Glu Glu Asn Ser Tyr Thr Gly Tyr Tyr Gly Met Asp Tyr
 1               5                  10              


<210> 27
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 27
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 28
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 28
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 29
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 29
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Lys Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 30
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 30
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Phe Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 31
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 31
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Trp Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 32
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 32
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Tyr Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 33
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 33
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Gly Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 34
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 34
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Phe Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 35
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 35
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Val Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 36
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 36
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Trp Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 37
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Phe Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 38
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 38
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Pro Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 39
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 39
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Val Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 40
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 40
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 41
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 41
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Thr Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 42
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 42
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Lys Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 43
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 43
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Lys Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 44
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 44
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Phe Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 45
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 45
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Tyr Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 46
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 46
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Phe Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 47
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 47
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Phe Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 48
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 48
Gln Val Gln Leu Val Ala Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Val Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 49
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 49
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Phe Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 50
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 50
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Tyr Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 51
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 51
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Phe Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 52
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 52
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Phe Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 53
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 53
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Val Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Asp Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 54
<211> 122
<212> PRT
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 54
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
            20                  25                  30          
Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45              
Gly Arg Val Asn Pro Tyr His Gly Gly Ala Thr Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Glu Asn Ser Tyr Thr Gly Tyr Tyr Gly Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120         


<210> 55
<211> 75
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 55
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc cgtgaaggtc 60
tcctgcaagg cttct                                                  75

<210> 56
<211> 30
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 56
ggatacacat tcacggacta ctacatggac                                  30

<210> 57
<211> 51
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 57
cgggttaatc cttaccatgg tggcgctacc tacaaccaga agttcaaggg c          51

<210> 58
<211> 39
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 58
gaggagaatt cttacgacgg ttattatggt atggactac                        39

<210> 59
<211> 366
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 59
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggata cacattcacg gactactaca tggactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gattggacgt gttaatcctt accatggtgg cgctacctac 180
aaccagaagt tcaagggcaa ggccacaatt accgttgaca aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagaggag 300
aattcttacg acggttatta tggtatggac tactggggcc aagggaccct ggtcaccgtc 360
tcctca                                                            366

<210> 60
<211> 366
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 60
caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc cgtgaaggtc 60
tcctgcaagg cttctggata cacattcacg gactactaca tggactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggacgg gttaatcctt accatggtgg cgctacctac 180
aaccagaagt tcaagggcag ggtgacaatt accgccgaca aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagaggag 300
aattcttacg acggttatta tggtatggac tactggggcc aagggaccct ggtcaccgtc 360
tcctca                                                            366

<210> 61
<211> 366
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 61
gaggtccaac tgcagcagtc tggacctgag ttggtgaagc ctggggcttc agtgaagatg 60
tcctgtaagg cttctggata cacattcacg gactactaca tggactgggt gaagcagagc 120
cacggagaaa gctttgagtg gattggacgt gttaatcctt accatggtgg cgctacctac 180
aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag aacagcctac 240
atggaactca acagcctgac atatgaggac tccgcggtct attactgtgc aagagaggag 300
aattcttacg acggttatta tggtatggac tactggggcc aagggaccac ggtcaccgtc 360
tcctca                                                            366

<210> 62
<211> 354
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 62
gaggtgaagc tgcaggagtc tggaggtggc ctggtgcagc ctggaggatc cctgaatctc 60
tcctgtacag cctcaggatt cgattttagt agatactgga tgagttgggc tcggcaggct 120
ccagggaaag ggcaggaatg gattggagaa attaatccag gaagcagtac gataaactat 180
acgccatctc taaaggataa attcatcatc tccagagaca acgccaaaaa tacgctgtac 240
ctgcaaatga gcaaagtgag atctgaggac acagcccttt attactgtgc aagacagggg 300
acttattata ctatggacta ctggggccaa gggaccacgg tcaccgtctc ctca       354

<210> 63
<211> 339
<212> DNA
<213> Artificial sequence

<220> 
<223> L284 Humanized murine anti-CD100 light chain

<400> 63
gacatcgtga tgacccagtc tccactctcc ctgcccgtct ctcctggaga gccggccacc 60
atcaactgca agtccagcca gagtctgttt aacagtggaa atcaaaagaa ctacttggcc 120
tggtacctgc agaagccagg gcagcctcct aaactgttga tctacggggc atccactagg 180
gaatctgggg tccctgatcg cttcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcagaatga tcatacttat 300
ccgtacactt ttggccaggg gaccaagctc gagatcaaa                        339

<210> 64
<211> 339
<212> DNA
<213> Artificial sequence

<220> 
<223> L124284 - humanized murine anti-CD100 light chain

<400> 64
gacattgtgc taacccagtc tccatcctcc ctgagtgtgt cagcaggaga gaaggtcact 60
atggactgca agtccagtca gagtctgttt aacagtggaa atcaaaagaa ctacttggcc 120
tggtaccacc agaaaccagg gcagcctcct aaactgttga tctacggggc atccactagg 180
gaatctgggg tccctgatcg cttcacaggc agtggatctg gaaccgattt cactcttacc 240
atcagcagtg tgcaggctga agacctggca gtttattact gtcaaaatga tcatacttat 300
ccgtacacgt tcggaggggg gaccaagctc gagatcaaa                        339

<210> 65
<211> 318
<212> DNA
<213> Artificial sequence

<220> 
<223> anti-CD100 variable domain -

<400> 65
gacatccaga tgacgcagtc tccatcctca ctgtctgcat ctctgggagg caaagtcacc 60
atcacttgca aggcaagcca agacattaac aagtatatat cttggtacca agacaagcct 120
ggaaaaggtc ctgggctgct catacattac acatctacat tacagccagg catcccatca 180
aggttcagtg gaagtgggtc tgggagagat tattccttca gcatcagcaa cctggagcct 240
gaagatattg caacttatta ttgtctacag tatgataatc tgtacacgtt cggagggggg 300
accaagctcg agatcaaa                                               318
